{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:24:20Z","timestamp":1790288660729,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40263-024-01089-w","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T04:01:57Z","timestamp":1715054517000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-1918","authenticated-orcid":false,"given":"Megan","family":"Galbally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4620-7691","authenticated-orcid":false,"given":"Karen","family":"Wynter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-547X","authenticated-orcid":false,"given":"Korinne","family":"Northwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-9741","authenticated-orcid":false,"given":"Susanna","family":"Every-Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"issue":"5","key":"1089_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410\u201372. https:\/\/doi.org\/10.1177\/0004867416641195.","journal-title":"Aust N Z J Psychiatry"},{"key":"1089_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.schres.2019.09.013","volume":"215","author":"Y Shimomura","year":"2020","unstructured":"Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophr Res. 2020;215:8\u201316. https:\/\/doi.org\/10.1016\/j.schres.2019.09.013.","journal-title":"Schizophr Res"},{"issue":"1","key":"1089_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3\u201378. https:\/\/doi.org\/10.1177\/0269881119889296.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1089_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2020","unstructured":"Correll CU, Martin A, Patel C, Benson C, Goulding R, Kern-Sliwa J, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia (Heidelb). 2020;8(1):5. https:\/\/doi.org\/10.1038\/s41537-021-00192-x.","journal-title":"Schizophrenia (Heidelb)"},{"issue":"5","key":"1089_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3109\/09540261.2010.515205","volume":"22","author":"KM Abel","year":"2010","unstructured":"Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22(5):417\u201328. https:\/\/doi.org\/10.3109\/09540261.2010.515205.","journal-title":"Int Rev Psychiatry"},{"key":"1089_CR6","volume-title":"Psychopharmacology and pregnancy: treatment efficacy, risks, and guidelines","author":"KM Abel","year":"2014","unstructured":"Abel KM, Howard LM. Schizophrenia, psychopharamacology and pregnancy. In: Galbally MS, Lewis MA, editors. Psychopharmacology and pregnancy: treatment efficacy, risks, and guidelines. Berlin: Springer; 2014."},{"key":"1089_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/916198","volume":"2012","author":"S Ochoa","year":"2012","unstructured":"Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment. 2012;2012: 916198. https:\/\/doi.org\/10.1155\/2012\/916198.","journal-title":"Schizophr Res Treatment"},{"key":"1089_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/0020764019897286","author":"L Suparare","year":"2020","unstructured":"Suparare L, Watson SJ, Binns R, Frayne J, Galbally M. Is intimate partner violence more common in pregnant women with severe mental illness? A retrospective study. Int J Soc Psychiatry. 2020. https:\/\/doi.org\/10.1177\/0020764019897286.","journal-title":"Int J Soc Psychiatry"},{"key":"1089_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12888-015-0451-8","volume":"15","author":"CL Taylor","year":"2015","unstructured":"Taylor CL, Stewart R, Ogden J, Broadbent M, Pasupathy D, Howard LM. The characteristics and health needs of pregnant women with schizophrenia compared with bipolar disorder and affective psychoses. BMC Psychiatry. 2015;15:88. https:\/\/doi.org\/10.1186\/s12888-015-0451-8.","journal-title":"BMC Psychiatry"},{"key":"1089_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2019.03.002","volume":"53","author":"J Kulkarni","year":"2019","unstructured":"Kulkarni J, Butler S, Riecher-R\u00f6ssler A. Estrogens and SERMS as adjunctive treatments for schizophrenia. Front Neuroendocrinol. 2019;53: 100743. https:\/\/doi.org\/10.1016\/j.yfrne.2019.03.002.","journal-title":"Front Neuroendocrinol"},{"issue":"2","key":"1089_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0004867416667234","volume":"51","author":"J Kulkarni","year":"2017","unstructured":"Kulkarni J, Galletly C. Improving safety for women in psychiatry wards. Aust N Z J Psychiatry. 2017;51(2):192\u20134. https:\/\/doi.org\/10.1177\/0004867416667234.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"1089_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s2215-0366(16)30209-7","volume":"4","author":"LM Howard","year":"2017","unstructured":"Howard LM, Ehrlich AM, Gamlen F, Oram S. Gender-neutral mental health research is sex and gender biased. Lancet Psychiatry. 2017;4(1):9\u201311. https:\/\/doi.org\/10.1016\/s2215-0366(16)30209-7.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"1089_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41593-021-00806-8","volume":"24","author":"RM Shansky","year":"2021","unstructured":"Shansky RM, Murphy AZ. Considering sex as a biological variable will require a global shift in science culture. Nat Neurosci. 2021;24(4):457\u201364. https:\/\/doi.org\/10.1038\/s41593-021-00806-8.","journal-title":"Nat Neurosci"},{"issue":"4","key":"1089_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/jcp.0000000000000346","volume":"35","author":"JM Kane","year":"2015","unstructured":"Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367\u201373. https:\/\/doi.org\/10.1097\/jcp.0000000000000346.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1089_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41537-021-00170-3","volume":"7","author":"S Hoekstra","year":"2021","unstructured":"Hoekstra S, Bartz-Johannessen C, Sinkeviciute I, Reitan SK, Kroken RA, L\u00f8berg EM, et al. Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophr. 2021;7(1):39. https:\/\/doi.org\/10.1038\/s41537-021-00170-3.","journal-title":"NPJ Schizophr"},{"issue":"3","key":"1089_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/yco.0000000000000243","volume":"29","author":"MB Crawford","year":"2016","unstructured":"Crawford MB, DeLisi LE. Issues related to sex differences in antipsychotic treatment. Curr Opin Psychiatry. 2016;29(3):211\u20137. https:\/\/doi.org\/10.1097\/yco.0000000000000243.","journal-title":"Curr Opin Psychiatry"},{"key":"1089_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1096366","volume":"14","author":"Y Shan","year":"2023","unstructured":"Shan Y, Cheung L, Zhou Y, Huang Y, Huang RS. A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications. Front Pharmacol. 2023;14: 1096366. https:\/\/doi.org\/10.3389\/fphar.2023.1096366.","journal-title":"Front Pharmacol"},{"key":"1089_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-244x-8-32","volume":"8","author":"G Morken","year":"2008","unstructured":"Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32. https:\/\/doi.org\/10.1186\/1471-244x-8-32.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"1089_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/14656566.2018.1465563","volume":"19","author":"A Gonz\u00e1lez-Rodr\u00edguez","year":"2018","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Seeman MV. Pharmacotherapy for schizophrenia in postmenopausal women. Expert Opin Pharmacother. 2018;19(8):809\u201321. https:\/\/doi.org\/10.1080\/14656566.2018.1465563.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1089_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/schbul\/sbac139","volume":"49","author":"IE Sommer","year":"2023","unstructured":"Sommer IE, Brand BA, Gangadin S, Tanskanen A, Tiihonen J, Taipale H. Women with schizophrenia-spectrum disorders after menopause: a vulnerable group for relapse. Schizophr Bull. 2023;49(1):136\u201343. https:\/\/doi.org\/10.1093\/schbul\/sbac139.","journal-title":"Schizophr Bull"},{"issue":"5","key":"1089_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","volume":"25","author":"T Kishimoto","year":"2012","unstructured":"Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25(5):415\u201329. https:\/\/doi.org\/10.1097\/YCO.0b013e328355e1ac.","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"1089_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/schbul\/sbac152","volume":"49","author":"M Solmi","year":"2023","unstructured":"Solmi M, Lahteenvuo M, Correll CU, Tanskanen A, Tiihonen J, Taipale H. Antipsychotic use and risk of low-energy fractures in people with schizophrenia: a nationwide nested case-control study in Finland. Schizophr Bull. 2023;49(1):78\u201389. https:\/\/doi.org\/10.1093\/schbul\/sbac152.","journal-title":"Schizophr Bull"},{"issue":"10","key":"1089_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","volume":"8","author":"H Taipale","year":"2021","unstructured":"Taipale H, Solmi M, Lahteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883\u201391. https:\/\/doi.org\/10.1016\/S2215-0366(21)00241-8.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"1089_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/acps.12313","volume":"130","author":"B Stubbs","year":"2014","unstructured":"Stubbs B, De Hert M, Sepehry AA, Correll CU, Mitchell AJ, Soundy A, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130(6):470\u201386. https:\/\/doi.org\/10.1111\/acps.12313.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1089_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/YCO.0000000000000597","volume":"33","author":"P Fernando","year":"2020","unstructured":"Fernando P, Sommer IEC, Hasan A. Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia? Curr Opin Psychiatry. 2020;33(3):192\u20139. https:\/\/doi.org\/10.1097\/YCO.0000000000000597.","journal-title":"Curr Opin Psychiatry"},{"issue":"11","key":"1089_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/s2215-0366(20)30341-2","volume":"7","author":"E Johnsen","year":"2020","unstructured":"Johnsen E, Kroken RA, L\u00f8berg EM, Rettenbacher M, Joa I, Larsen TK, et al. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. Lancet Psychiatry. 2020;7(11):945\u201354. https:\/\/doi.org\/10.1016\/s2215-0366(20)30341-2.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1089_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","volume":"29","author":"TS Stroup","year":"2003","unstructured":"Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15\u201331. https:\/\/doi.org\/10.1093\/oxfordjournals.schbul.a006986.","journal-title":"Schizophr Bull"},{"issue":"6","key":"1089_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/10398560701689186","volume":"15","author":"P Bick","year":"2007","unstructured":"Bick P, Knoesen N, Castle D. Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists. Australas Psychiatry. 2007;15(6):465\u20139. https:\/\/doi.org\/10.1080\/10398560701689186.","journal-title":"Australas Psychiatry"},{"issue":"5","key":"1089_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/10673220701679838","volume":"15","author":"TC Manschreck","year":"2007","unstructured":"Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007;15(5):245\u201358. https:\/\/doi.org\/10.1080\/10673220701679838.","journal-title":"Harv Rev Psychiatry"},{"issue":"3","key":"1089_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1017\/S0033291700035765","volume":"26","author":"G Lewis","year":"1996","unstructured":"Lewis G. DSM-IV. Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association. Psychol Med. 1996;26(3):651\u20132. https:\/\/doi.org\/10.1017\/S0033291700035765.","journal-title":"Psychol Med"},{"issue":"2","key":"1089_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"7","key":"1089_CR32","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"issue":"4","key":"1089_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-r","volume":"3","author":"D Addington","year":"1990","unstructured":"Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247\u201351. https:\/\/doi.org\/10.1016\/0920-9964(90)90005-r.","journal-title":"Schizophr Res"},{"key":"1089_CR34","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Washington: US Department of Health, Education, and Welfare, Public Health Service; 1976."},{"key":"1089_CR35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u20136. https:\/\/doi.org\/10.1192\/bjp.154.5.672.","journal-title":"Br J Psychiatry"},{"key":"1089_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139. https:\/\/doi.org\/10.1111\/j.1600-0447.1970.tb02066.x.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"1\u20133","key":"1089_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","volume":"101","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101(1\u20133):273\u201386. https:\/\/doi.org\/10.1016\/j.schres.2007.12.487.","journal-title":"Schizophr Res"},{"key":"1089_CR38","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum; 1988."},{"issue":"6","key":"1089_CR39","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/schbul\/sbab063","volume":"47","author":"JM Rubio","year":"2021","unstructured":"Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull. 2021;47(6):1611\u201320. https:\/\/doi.org\/10.1093\/schbul\/sbab063.","journal-title":"Schizophr Bull"},{"key":"1089_CR40","doi-asserted-by":"publisher","first-page":"204512532312115","DOI":"10.1177\/20451253231211575","volume":"13","author":"R Patel","year":"2023","unstructured":"Patel R, Brinn A, Irving J, Chaturvedi J, Gudiseva S, Correll CU, et al. Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data. Ther Adv Psychopharmacol. 2023;13:20451253231211576. https:\/\/doi.org\/10.1177\/20451253231211575.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"10","key":"1089_CR41","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/brainsci12101342","volume":"12","author":"A Gonz\u00e1lez-Rodr\u00edguez","year":"2022","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Monreal JA, Seeman MV. The effect of menopause on antipsychotic response. Brain Sci. 2022;12(10):1342. https:\/\/doi.org\/10.3390\/brainsci12101342.","journal-title":"Brain Sci"},{"key":"1089_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114738","volume":"316","author":"MV Seeman","year":"2022","unstructured":"Seeman MV. Sex\/gender differences in schizophrenia: thinking back and thinking forward. Psychiatry Res. 2022;316: 114738. https:\/\/doi.org\/10.1016\/j.psychres.2022.114738.","journal-title":"Psychiatry Res"},{"issue":"1","key":"1089_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ajo.12986","volume":"60","author":"M Galbally","year":"2020","unstructured":"Galbally M, Frayne J, Watson SJ, Morgan V, Snellen M. The association between gestational diabetes mellitus, antipsychotics and severe mental illness in pregnancy: a multicentre study. Aust N Z J Obstet Gynaecol. 2020;60(1):63\u20139. https:\/\/doi.org\/10.1111\/ajo.12986.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"1089_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euroneuro.2018.11.1103","volume":"29","author":"M Galbally","year":"2019","unstructured":"Galbally M, Frayne J, Watson SJ, Snellen M. Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: a multicentre study. Eur Neuropsychopharmacol. 2019;29(1):57\u201365. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.11.1103.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1089_CR45","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/070674370104600608","volume":"46","author":"A Labelle","year":"2001","unstructured":"Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. Can J Psychiatry. 2001;46(6):534\u201341. https:\/\/doi.org\/10.1177\/070674370104600608.","journal-title":"Can J Psychiatry"},{"issue":"10","key":"1089_CR46","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2217\/pgs-2018-0053","volume":"19","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, de Leon J, Diaz FJ. Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants. Pharmacogenomics. 2018;19(10):815\u201323. https:\/\/doi.org\/10.2217\/pgs-2018-0053.","journal-title":"Pharmacogenomics"},{"issue":"7","key":"1089_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2165\/00002018-200629070-00004","volume":"29","author":"W Aichhorn","year":"2006","unstructured":"Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 2006;29(7):587\u201398. https:\/\/doi.org\/10.2165\/00002018-200629070-00004.","journal-title":"Drug Saf"},{"issue":"2","key":"1089_CR48","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/15622970600685424","volume":"7","author":"S Kasper","year":"2006","unstructured":"Kasper S, Winkler D. Addressing the limitations of the CATIE study. World J Biol Psychiatry. 2006;7(2):126\u20137. https:\/\/doi.org\/10.1080\/15622970600685424.","journal-title":"World J Biol Psychiatry"},{"issue":"1688","key":"1089_CR49","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2015.0119","volume":"371","author":"DL Maney","year":"2016","unstructured":"Maney DL. Perils and pitfalls of reporting sex differences. Philos Trans R Soc Lond B Biol Sci. 2016;371(1688): 20150119. https:\/\/doi.org\/10.1098\/rstb.2015.0119.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"2","key":"1089_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/YCO.0b013e328350360e","volume":"25","author":"J Kulkarni","year":"2012","unstructured":"Kulkarni J, Hayes E, Gavrilidis E. Hormones and schizophrenia. Curr Opin Psychiatry. 2012;25(2):89\u201395. https:\/\/doi.org\/10.1097\/YCO.0b013e328350360e.","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"1089_CR51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41467-023-35808-6","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Shan Y, Zhang W, Lee AM, Li F, Stranger BE, et al. Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes. Nat Commun. 2023;14(1):175. https:\/\/doi.org\/10.1038\/s41467-023-35808-6.","journal-title":"Nat Commun"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01089-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01089-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01089-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T03:21:19Z","timestamp":1718594479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01089-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01089-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"7 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. The data utilised were supported with funds from the National Institute of Mental Health under contract NO1 MH90001. Dan Siskind is supported by a National Health and Medical Research Council Emerging Leadership Fellowship (GNT1194635).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Cristoph U. Correll has been a consultant and\/or advisor to or has received honoraria from AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Tolmar, Vertex and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax and Quantic. Megan Galbally, Karen Wynter, Dan Siskind, Korinne Northwood and Susanna Every-Palmer have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As outlined in the protocol paper for CATIE, a CATIE Ethics Committee, chaired by Paul Appelbaum, reviewed all human subjects ethics considerations [\n                      \n                      ].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"As outlined in the protocol paper, all prospective research participants were screened for decisional capacity [\n                      \n                      ]. Those who demonstrated adequate decisional capacity to participate in this research study were allowed to decide whether to enter the study. Those who choose to participate signed a consent form and entered the screening phase.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data are available from a data repository.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"IBM SPSS Statistics syntax is available from the first author on request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MG, DS and SE-P contributed to the study conception and design. Data access was provided by CC and DS. Material preparation and data analysis were performed by KW. The first draft of the manuscript was written by MG and KW and all authors commented on previous versions of the manuscript. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}